Overall, when compared to other PET tracers for restaging of PCa [3,6,8,11,14], no statistically significant differences were reported comparing radiolabeled Cho PET to PET with PSMA-targeted agents or 18F-FACBC, even if a superiority of PET with PSMA-targeted agents was demonstrated in detecting PCa lesions at low PSA levels (≤1 ng/mL). The gene discussed is FOLH1; the disease is posterior cortical atrophy.